Mission Wealth Management LP Invests $262,000 in Becton, Dickinson and Company (NYSE:BDX)

Mission Wealth Management LP purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the fourth quarter, Holdings Channel.com reports. The firm purchased 1,155 shares of the medical instruments supplier’s stock, valued at approximately $262,000.

Other large investors have also recently made changes to their positions in the company. Tompkins Financial Corp increased its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the last quarter. Radnor Capital Management LLC increased its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 48 shares during the last quarter. Wesbanco Bank Inc. increased its position in Becton, Dickinson and Company by 1.9% during the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 48 shares during the last quarter. S.A. Mason LLC increased its position in Becton, Dickinson and Company by 3.7% during the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after acquiring an additional 50 shares during the last quarter. Finally, Americana Partners LLC increased its position in Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 52 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of analyst reports. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $278.29.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,061 shares of company stock valued at $1,379,521 over the last three months. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Up 0.5 %

NYSE:BDX opened at $225.19 on Friday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The company has a 50-day moving average of $232.96 and a 200 day moving average of $232.78. The firm has a market cap of $64.66 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company announced that its board has approved a stock buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.